Cost of Nosocomial Outbreak Caused by NDM-1-Containing Klebsiella pneumoniae in the Netherlands, October 2015-January 2016

Emerg Infect Dis. 2017 Sep;23(9):1574-1576. doi: 10.3201/eid2309.161710.

Abstract

During October-December 2015, 29 patients in a hospital in the Netherlands acquired nosocomial infection with a multidrug-resistant, New Delhi-metallo-β-lactamase-positive Klebsiella pneumoniae strain. Extensive infection control measures were needed to stop this outbreak. The estimated economic impact of the outbreak was $804,263; highest costs were associated with hospital bed closures.

Keywords: CPE; ESBL; Enterobacteriaceae; HRMO; Klebsiella pneumoniae; NDM-1; antimicrobial resistance; bacteria; costs; economic; extended-spectrum β-lactamase; nosocomial; outbreak; the Netherlands.

MeSH terms

  • Anti-Bacterial Agents / economics
  • Anti-Bacterial Agents / therapeutic use
  • Carrier State
  • Cost of Illness*
  • Cross Infection / diagnosis
  • Cross Infection / economics*
  • Cross Infection / epidemiology
  • Cross Infection / microbiology
  • Disease Outbreaks / economics*
  • Gene Expression
  • Hospitals
  • Humans
  • Incidence
  • Klebsiella Infections / diagnosis
  • Klebsiella Infections / economics*
  • Klebsiella Infections / epidemiology
  • Klebsiella Infections / microbiology
  • Klebsiella pneumoniae / drug effects
  • Klebsiella pneumoniae / enzymology
  • Klebsiella pneumoniae / genetics*
  • Klebsiella pneumoniae / isolation & purification
  • Microbial Sensitivity Tests
  • Netherlands / epidemiology
  • Plasmids / chemistry
  • Plasmids / metabolism
  • beta-Lactamases / genetics*
  • beta-Lactamases / metabolism
  • beta-Lactams / economics
  • beta-Lactams / therapeutic use

Substances

  • Anti-Bacterial Agents
  • beta-Lactams
  • beta-Lactamases
  • beta-lactamase NDM-1